20 Years of Hepatitis C Management Among People Who Use Drugs in France

Hepatitis C, which affects nearly 50 million people worldwide, is a potentially fatal disease. People who inject drugs account for up to 70% of cases worldwide. In France, since 2004, Inserm, ANRS MIE, Santé publique France, and the Tours University Hospital have conducted the Coquelicot survey to estimate the prevalence and incidence of hepatitis C among drug users receiving care at treatment and harm reduction facilities. The latest results from this survey were recently published in the October issue of *Nature Communications*. They show a reduction of at least 50% in the prevalence and incidence of the disease among these populations. According to the authors, this decline likely reflects the combined effect of the widespread use of direct-acting antivirals and harm reduction policies. France is currently at a turning point and could achieve the WHO’s 2030 goals for the elimination of hepatitis C.

Hepatitis C affects nearly 50 million people worldwide. Transmitted through blood, it can be fatal, but effective treatments are now available to combat it: direct-acting antivirals (DAAs). The persistence of the disease is due to the lack of immunity after the virus has been cleared or after treatment. Added to this are inequalities in access to care. The WHO has set a goal of eliminating the disease by 2030.

Hepatitis C therefore remains a major public health challenge, particularly among people who use drugs. In high-income countries, injection drug use combined with the sharing of contaminated equipment is indeed one of the main modes of transmission: in Europe, 20 to 70% of cases result from injecting drug use.

In France, the Coquelicot survey was launched in 2004 by Inserm, the ANRS Emerging Infectious Diseases Unit (ANRS MIE), Santé publique France, and the Tours University Hospital to track trends in hepatitis C among people who use drugs receiving care in treatment and harm reduction facilities; it was then repeated in 2013 and 2023. To date, it is the only epidemiological and sociological survey involving biological samples that allows for the estimation of hepatitis C prevalence and associated factors in a representative sample of this population in France. 

The results of the latest edition of the survey, which have just been published in *Nature Communications*, show a sharp decrease (-61%) in the number of new cases of hepatitis C per year among people who inject drugs: the incidence thus fell from 6.5 to 2.4 per 100 person-years* between 2013 and 2023. During this period, the prevalence of active hepatitis C virus (HCV) infection was cut in half among all drug users (19.4% in 2013 versus 9.5% in 2023), as well as among people who inject drugs (29.6% in 2013 versus 14.5% in 2023). These estimates were generated through mathematical modeling based on biological data on HCV RNA, which allowed for the consideration of active infections only. 

Harm reduction policies have been evaluated in many countries and have proven effective, but they are nonetheless regularly called into question, which can lead to the closure of certain centers. These closures expose people who use drugs to increased health risks. It is essential to strengthen these policies by drawing on scientific evidence.

Dr. Marie Jauffret-Roustide, Research Director at Inserm, at the Center for the Study of Social Movements (Inserm/CNRS/EHESS), and scientific director of the Coquelicot study since 2004

The authors of the article attribute these encouraging results to the current French healthcare model, which is characterized by widespread screening (in terms of tools and “outreach”** approaches), widespread availability of hepatitis C treatments for all populations, including the most vulnerable, and access to harm reduction policies. 

These harm reduction policies include several public health measures such as access to clean syringes, the prescription of opioid agonist treatments (methadone and buprenorphine) available throughout France, and addiction care centers (safe consumption rooms), which are currently available only in Paris and Strasbourg.

The results indicate that France is on track to meet the elimination targets set by the WHO by 2030. To maintain this trend and prevent any resurgence or spike in infections, it is crucial that harm reduction, access to testing and care, and the prevention of reinfection remain a top priority. 

* This means that if we follow 100 people for one year, we can expect an average of 2.4 new cases.

**The “outreach” approach encourages professionals and institutions to reach out to people to intervene early, before difficulties become entrenched, with the goal of identification and prevention rather than remediation.

Reference: Chiara E. Sabbatini, Yann Le Strat, Christophe Bonaldi, Cécile Brouard, Martin Audran, Leïla Sabon, Jean-Baptiste Richard, Amélie David, Catherine Gaudy-Graffin, Stéphane Chevaliez, Francis Barin, Karl Stefic, and Marie Jauffret-Roustide.

HCV Incidence and Prevalence Trends Among People Who Use Drugs in France, 2004–2023. Nature Communications 2026. 

Our latest news

news

Odissé Dataviz Challenge: Winners Honored at the Santé publique France...

Appel à candidatures d'experts pour le remplacement d’un membre « sage-femme » du Comité national d'experts sur la mortalité maternelle (CNEMM)

news

Call for Nominations to Fill Vacancies on the National Reference Centers...

news

Public Health France Conference: November 9, 2026